Related Experiment Video
Updated: Jun 6, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Necroptosis: a novel therapeutic target for glioblastoma
Yu-Gang Jiang1, Yong Peng, Koku Sossou Koussougbo
1Department of Neurosurgery, Second Xiangya Hospital of Central South University, Changsha, Hunan Province 410011, China. 13707315567@139.com
Abstract:
Glioblastoma or glioblastoma multiforme (GBM) is the most encountered and malignant form of brain tumors in clinical practice. In spite of optimal and early treatment, the life expectancy of patients with GBM remains poor. It is believed that dysfunction of apoptosis underlies GBM tumorigenesis, proliferation and resistance to chemotherapy and radiotherapy. Although GBM is defective in apoptotic process, pathologic and radiologic observations almost always reveal obvious necrosis foci within GBM. Necrosis seems to be related with GBM proliferation, angiogenesis and invasion. However, tumor cell necrosis induced by various therapies has a potential therapeutic value. Just recently, necrotic cell death is considered as a regulated and controlled process, like apoptosis, termed necroptosis or programmed necrosis. Induction of apoptosis has not made any significant achievements in the treatment of GBM mainly because the tumor cells are apoptosis-resistant. We may achieve a better result by modulating the necroptosis of GBM thus circumvent the apoptosis resistance. Albeit specific molecular pathways involved in GBM necroptosis is not clear and much more studies are needed to confirm the effects of therapy-induced necroptosis on GBM, it provides us with a new direction in the treatment of GBM.
Insights
Glioblastoma multiforme (GBM) is a deadly brain cancer resistant to apoptosis. Targeting necroptosis, a programmed form of necrosis, may offer a new therapeutic strategy to overcome this resistance and improve patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Cell Death Pathways
Background:
- Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor prognosis despite treatment.
- Apoptosis dysfunction is implicated in GBM development, proliferation, and therapeutic resistance.
- Necrosis, often observed in GBM, is increasingly recognized as a regulated process (necroptosis) with therapeutic potential.
Purpose of the Study:
- To explore necroptosis as a potential therapeutic target for glioblastoma multiforme.
- To investigate strategies for circumventing apoptosis resistance in GBM cells.
- To identify new treatment directions for glioblastoma.
Main Methods:
- Review of existing literature on GBM, apoptosis, and necroptosis.
- Analysis of pathological and radiological observations of necrosis in GBM.
- Exploration of therapeutic implications of modulating programmed cell death pathways.
Main Results:
- GBM cells exhibit resistance to apoptosis, limiting treatment efficacy.
- Necrosis is a common feature in GBM and may be linked to tumor progression.
- Necroptosis, or programmed necrosis, presents a viable alternative cell death pathway to target GBM.
Conclusions:
- Targeting necroptosis offers a promising new therapeutic avenue for glioblastoma multiforme.
- Further research is needed to elucidate specific molecular pathways of GBM necroptosis.
- Modulating necroptosis could overcome apoptosis resistance and improve GBM treatment outcomes.
